Screening of Hepatitis C virus in blood donors over 11 years
Main Article Content
Keywords
Hepatitis C, Blood Donors, Nucleic Acid Amplification Techniques, Blood Safety
Abstract
Abstract
Background: HCV infection remains a global concern due to its often asymptomatic course and the potential for transfusion transmission during the window period. In this setting, nucleic acid testing (NAT) can detect early viremia that is not yet identifiable by serology, thereby strengthening blood safety.
Objective: To quantify HCV NAT yield (NAT-reactive donations with non-reactive anti-HCV serology, consistent with window-period detection) in blood donors using combined NAT and serology over an 11-year period.
Material and methods: Cross-sectional, observational study including 568,569 donations recorded at the CMN Siglo XXI Blood Bank (2014–2025). NAT and serology results were analyzed in accordance with NOM-253-SSA1-2012 to identify donations with a NAT-reactive/serology-non-reactive pattern.
Results: One NAT-reactive/serology-non-reactive case was identified, consistent with window-period infection. The NAT yield rate was 0.18 per 100,000 donations (1.8 per million). No risk factors or coinfections were reported, indicating that serology alone would have missed the infection. Because only one case was documented over 11 years, population-level inferences and epidemiologic impact estimates are not supported.
Conclusions: In a large cohort within a very low-frequency setting, NAT identified a potentially infectious donation that serology did not detect. Although the absolute yield was low, each detected case is relevant to transfusion safety. Expanding NAT coverage and strengthening voluntary donation are recommended to optimize transfusion safety in Mexico.
References
1. Topi S, Gaxhja E, Charitos LA, et al. Hepatitis C Virus: History and Current Knowledge. Gastroenterol Insights. 2024;15:676-707.
2. Laguna-Meraz S, Jose-Abrego A, Roman S, , et al. Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico. Viruses. 2024;16:1259.
3. Torrents de la Peña A, Sliepen K, Eshun-Wilson L, et al. Structure of the hepatitis C virus E1E2 glycoprotein complex. Science. 2022;378(6617):263-269.
4. Sallam M, Khalil R. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms. 2024;12:1035.
5. Shahin D, Aly R, Ghannam M, A, et al. A comparative analysis between NAT and chemiluminescence in detection of transfusion transmitted viruses in two main university blood transfusion centers. Sci Rep. 2025;15:20109.
6. Faddy HM, Osiowy C, Custer B, et al. International review of blood donation nucleic acid amplification testing. Vox Sang. 2024;119:315-25.
7. Secretaría de Salud. NORMA Oficial Mexicana NOM-253-SSA1-2012, Para la disposición de sangre humana y sus componentes con fines terapéuticos. Diario Oficial de la Federación. 2012.
8. Comisión Federal para la Protección contra Riesgos Sanitarios. PROYECTO de Norma Oficial Mexicana NOM-253-SSA1-2024, Para la disposición de sangre humana y sus componentes con fines terapéuticos. Diario Oficial de la Federación. 2024.
9. Mejía-Aguirre B, Luna-Vargas AK, Benitez-Arvizu G. Seroprevalencia de agentes infecciosos en donadores de sangre y sus componentes. Rev Med Inst Mex Seguro Soc. 2024;63(2).
10. Guerrero-García JJ, Zúñiga-Magaña AG, Barrera-De León JC, et al. Retrospective Study of the Seroprevalence of HIV, HCV, and HBV in Blood Donors at a Blood Bank of Western Mexico. Pathogens. 2021;10:878.
11. Mejía-Domínguez AM, Soster-Contreras MA, Campos-Morales N, et al. Prevalence of HIV, Syphilis, and Hepatitis B and C Among Blood Donors in a Tertiary Care Hospital in Mexico. Venereology. 2024;3:172-182.
12. Sosa-Jurado F, Palencia-Lara R, Xicoténcatl-Grijalva C, et al. Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico. Viruses. 2023;15:1331.
13. Uribe-Noguez LA, Prieto-Torres ME, Uribe-Noguez LO, et al. Prevalence and Risk Factors of Occult HCV Infection in the Adult Population of Mexico City. Viruses. 2025;17:236.
14. Madeira HS, Silva CM, Scapini NC, et al. Correlation between serology and nucleic acid amplification test in blood donors who are reactive for hepatitis B virus, hepatitis C and human immunodeficiency virus. Saudi Pharm J. 2021;29:586-596.
15. Wu D, Feng F, Wang X, et al. The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review. BMC Infect Dis. 2022;22:279.
16. Bloch EM, Kipiani E, Shadaker S, et al. Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. Transfusion. 2020;60(6):1243-1252.
17. Steele WR, Dodd RY, Notari EP, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS). Transfusion. 2020;60.
18. Wang T, Zhang J. Application analysis of two nucleic acid detection systems in blood detection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus. PeerJ. 2025;13:e20365.
19. Cardoso M, Ragan I, Hartson L, et al. Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies. Pathogens. 2023;12:911.
20. Songtanin B, Nugent K. Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection. Biology. 2023;12:23.
21. Alabdallat NG, Alanazi H, Alyenbaawi H, et al. Evaluation of Hepatitis C Virus Nucleic Acid Testing and HIV Nucleic Acid Testing for Blood Donors. J Med Pharm Allied Sci. 2023;12.
22. Ju S, Lee C, Jung J, et al. Transition from Secondary Blood Test to Nucleic Acid Amplification for Safe Allograft Transplantation. Clin Orthop Surg. 2021;13:564-568.
23. Campos-Valdez M, Castro-García MA, Ramos-Márquez ME, et al. An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies. Microorganisms. 2024;12:1368.
24. Stroffolini T, Stroffolini G. Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review. Viruses. 2024;16:1115.
25. Dimech W. The Standardization and Control of Serology and Nucleic Acid Testing for Infectious Diseases. Clin Microbiol Rev. 2021;35(1).
26. Centro Nacional de la Transfusión Sanguínea. En 2023 en México hubo 1.6 millones de donaciones de sangre. Ciudad de México: Secretaría de Salud. 2024.
27. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45:101596.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.